HAWTHORNE, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that data from its recently-completed Fampridine-SR Phase 3 trial (MS-F204) will be presented during a poster session at the World Congress in Treatment and Research in MS Meeting (ACTRIMS, ECTRIMS and LACTRIMS) on Saturday, September 20, 2008 in Montreal, Canada. The Company previously announced top-line data from MS-F204 on June 2, 2008, and the poster will provide additional data from that clinical trial.
